false 0001267565 0001267565 2024-05-16 2024-05-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 16, 2024

 

COLLEGIUM PHARMACEUTICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Virginia   001-37372   03-0416362
(State or Other Jurisdiction
of Incorporation or Organization)		   (Commission File Number)   (IRS Employer Identification
No.)

 

100 Technology Center Drive
Suite 300
Stoughton, MA 02072
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 713-3699

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share COLL The NASDAQ Global Select Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

On May 16, 2024, Collegium Pharmaceutical, Inc. (the “Company”) held its 2024 Annual Meeting of Shareholders (the “Annual Meeting”). A total of 32,705,747 shares of common stock of the Company were entitled to vote as of March 27, 2024, the record date for the Annual Meeting, of which 31,059,529 were present in person or by proxy at the Annual Meeting.  The following is a summary of the final voting results for each matter presented to shareholders.

 

PROPOSAL 1:

 

Election of eight Directors to hold office until the 2025 Annual Meeting of Shareholders.

 

Nominee   For   Against   Abstentions   Broker Non-Votes
Rita Balice-Gordon   28,105,388   568,305   24,995   2,360,841
Garen Bohlin   28,404,221   268,899   25,568   2,360,841
John Fallon   25,399,411   3,273,949   25,328   2,360,841
John Freund   28,384,244   289,466   24,978   2,360,841
Michael Heffernan   26,121,329   2,552,363   24,996   2,360,841
Neil McFarlane   28,442,938   230,764   24,986   2,360,841
Gwen Melincoff   28,081,458   592,076   25,154   2,360,841
Gino Santini   28,284,684   389,000   25,004   2,360,841

 

Each of Rita Balice-Gordon, Garen Bohlin, John Fallon, John Freund, Michael Heffernan, Neil McFarlane, Gwen Melincoff, and Gino Santini was re-elected by the Company’s shareholders as Directors to hold office until the 2025 Annual Meeting of Shareholders.

 

PROPOSAL 2:

 

Approval of, on an advisory basis, the compensation of the Company’s named executive officers.

 

For   Against   Abstentions   Broker Non-Votes
28,311,783   350,755   36,150   2,360,841

 

On an advisory basis, the Company’s shareholders approved the compensation of the Company’s named executive officers.

 

PROPOSAL 3:

 

Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

 

For   Against   Abstentions   Broker Non-Votes
30,106,217   92,255   23,996   837,061

 

Proposal 3 was approved by the Company’s shareholders.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 20, 2024 Collegium Pharmaceutical, Inc.
     
  By: /s/ Colleen Tupper
    Name: Colleen Tupper
    Title: Executive Vice President and Chief Financial Officer

 

 

 

v3.24.1.1.u2
Cover
May 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 16, 2024
Entity File Number 001-37372
Entity Registrant Name COLLEGIUM PHARMACEUTICAL, INC.
Entity Central Index Key 0001267565
Entity Tax Identification Number 03-0416362
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 100 Technology Center Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Stoughton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02072
City Area Code 781
Local Phone Number 713-3699
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol COLL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Collegium Pharmaceutical Charts.
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Collegium Pharmaceutical Charts.